Ambit Biosciences Receives $30,000,000 Series D Funding Round

  • Feed Type
  • Date
    6/10/2011
  • Company Name
    Ambit Biosciences
  • Mailing Address
    4215 Sorrento Valley Blvd. San Diego, CA 92121
  • Company Description
    Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for the treatment of cancer.
  • Website
    http://www.ambitbio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $30,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    This recent capital raise will allow us to continue the clinical development of our lead product candidate, AC220, which is currently in a Phase 2 pivotal trial in Acute Myeloid Leukemia. This financing also provides for the continued development of our other two clinical assets, AC430 and AC480, both of which are in Phase 1 trials.
  • M&A Terms
  • Venture Investor
    Apposite Capital
  • Venture Investor
    OrbiMed
  • Venture Investor
    Forward Ventures
  • Venture Investor
    MedImmune Ventures
  • Venture Investor
    Growthworks Capital
  • Venture Investor
    Roche Venture Fund
  • Venture Investor
    GeneChem
  • Venture Investor
    GIMV
  • Venture Investor
    Radius Ventures
  • Venture Investor
    NovaQuest
  • Venture Investor
    Horizon Technology Finance

By posting a comment, you agree to our terms and conditions.